

HSV-1/2 (0119): sc-57847

BACKGROUND

Two serotypes of the herpes simplex virus, HSV-1 (also known as type 1 or oral) and HSV-2 (type 2 or genital), can establish lifelong latent infections within sensory ganglia. Periodically, the virus reactivates and can cause recurrent cold sores, encephalitis and eye and genital infections. HSV-1 usually establishes latency in the trigeminal ganglion, a collection of nerve cells near the ear. From there, it tends to recur on the lower lip or face. HSV-2 usually resides in the sacral ganglion at the base of the spine. From there, it reiterates in the genital area. When no symptoms are present, HSV lies dormant in the bodies of the nerve cells. During an outbreak, though, it replicates within axons near the skin. Once the outbreak subsides, the virus then retreats along the nerve until it remains only in the nerve body. Dormancy of the virus within the nerve bodies contributes to its difficulty of treatment. There is currently no known cure or vaccine for HSV. All herpes viruses are morphologically identical: they have a large double stranded DNA genome and a virion consisting of an icosahedral nucleocapsid which is surrounded by a lipid bilayer envelope.

REFERENCES

1. Sindhi, R. 2006. HSV infection and immunosuppression. *Liver Transpl.* 12: 1906-1907.
2. Chu, K., et al. 2006. Association between HSV-2 and HIV-1 viral load in semen, cervico-vaginal secretions and genital ulcers of Thai men and women. *Int. J. STD AIDS* 17:681-686.
3. Lowhagen, G.B., et al. 2006. The microenvironment of vulvar skin in women with symptomatic and asymptomatic herpes simplex virus type 2 (HSV-2) infection. *J. Eur. Acad. Dermatol. Venerol.* 20:1086-1089.
4. Haddow, L.J., et al. 2006. Herpes simplex virus type 2 (HSV-2) infection in women attending an antenatal clinic in the South Pacific island nation of Vanuatu. *Sex. Transm. Dis.* E-Published ahead of print.
5. Margolis T.P., et al. 2007. HSV-2 establishes latent infection in a different population of ganglionic neurons than HSV-1: role of LAT. *J. Virol.* 81: 1872-1878
6. Golembewski, E.K., et al. 2007. The HSV-2 protein ICP10PK prevents neuronal apoptosis and loss of function in an *in vivo* model of neurodegeneration associated with glutamate excitotoxicity. *Exp. Neurol.* 203: 381-393
7. Iqbal, J., et al. 2007. Development and validation of a capillary electrophoresis method for the characterization of herpes simplex virus type 1 (HSV-1) thymidine kinase substrates and inhibitors. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 846: 281-290.
8. Robe, P.A., et al. 2007. Sufasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. *Int. J. Oncol.* 30: 283-290.

SOURCE

HSV-1/2 (0119) is a mouse monoclonal antibody raised against HSV-1/2 infected cells.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

HSV-1/2 (0119) is recommended for detection of specific nuclear (regulatory) protein of HSV-1 and -2 origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.